Camrelizumab Combined With Radiotherapy for Adjuvant Treatment of Esophageal Squamous Cell Carcinoma After Surgery

Sponsor
Fuzhou General Hospital
Study ID
NCT04741490
Status
Unknown

Conditions

  • Esophageal Squamous Cell Carcinomas

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    PD-1antibodies，200mg ivgtt Q3W
  • radiotherapy — RADIATION
    45-55Gy/1.8～2.0Gy

Study Details

This is an investigator-initiated, single-arm, single-center, exploratory clinical study.The study population consisted of patients with R0 resection of esophageal squamous cell carcinoma who had not received radiation therapy.The purpose of this study was to evaluate the efficacy and safety of carrelizumab combined with radiotherapy in the adjuvant treatment of esophageal squamous cell carcinoma after surgery.About 20 subjects are planned to be enrolled in this study.Drug regimen: Patients with esophageal squamous cell carcinoma received radiotherapy combined with carrilizumab adjuvant therapy for 6 cycles 1-3 months after R0 resection.

Key Dates

Start date
Feb 28, 2021
Status verified
Feb 2021
Primary completion
Aug 31, 2022
Completion
Aug 31, 2023

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: treatment group
    The adjuvant treatment of radiotherapy combined with carrilizumab lasted for 6 cycles

Primary Outcome Measure

1-year disease-free survival rate (1-year DFS) [ Time Frame: up to approximately 1 year ]

Central Contacts